Connect with us

US

Biden’s Judicial Nominees Have Diverse Backgrounds

Published

on

[ad_1]

Among those named on Tuesday are nominees with experience as military and family court judges, a county administrator and an intellectual property lawyer.

For the seventh circuit, Mr. Biden chose Candace Jackson-Akiwumi, an experienced litigator who was a federal public defender in Chicago for a decade, not a traditional résumé entry for an appeals court nominee. But progressives consider her to be emblematic of the type of candidates they hope Mr. Biden will select for other judicial openings around the country.

“It is critical that a diverse, qualified nominee be nominated for the Seventh Circuit,” said Russ Feingold, the former Democratic senator from Wisconsin who now heads the American Constitution Society. “The Seventh Circuit is currently all white judges and it is time to reverse that trend that was so accelerated by the Trump administration.”

Ms. Jackson-Akiwumi, currently a partner at the Washington law firm of Zuckerman Spaeder, is just one of the African-American candidates on Mr. Biden’s list, including Judge Jackson, a lower-level federal judge in the District of Columbia who is considered a top candidate if Mr. Biden has an opportunity to name someone to the Supreme Court.

The first judicial picks of a new presidency typically set the tone for the administration. The White House tightly controlled information about who was under consideration for nominations. With 68 slots now open and an additional 26 scheduled to become vacant later this year, liberal activists are encouraging the administration to be aggressive to counter the Mr. Trump’s choices, particularly since Democrats could lose control of the Senate in next year’s midterm elections.

White House officials said Mr. Biden was moving more quickly than Mr. Trump and other former presidents. By the end of March of his first year, Mr. Trump had named only one circuit court judge and no district court judges. Mr. Obama had named one circuit court judge and three district court judges. President George W. Bush did not name any judges until May of his first year in office, and President Bill Clinton until August.

From the start, Mr. Biden’s White House has made clear that it intends to put judges with different types of backgrounds on the federal bench as quickly as it can. In a letter in December, the incoming White House counsel, Dana Remus, told Democratic senators that Mr. Biden would be looking for judges from groups historically underrepresented on the bench.

[ad_2]

Source link

Continue Reading

US

NYPD releases video of gunman firing into group in the Bronx

Published

on

By

[ad_1]

New video tweeted by the NYPD Sunday shows a gunman wildly firing down a Bronx street into a group of people in Fordham Manor, leaving two men wounded, cops said.

“WANTED for ASSAULT: Do you know this guy?” the NYPD wrote on Twitter.

“On 6/25/21 at approx 11:10 PM, in front of 2710 Morris Ave in the Bronx, the suspect fired several rounds towards a group, striking a 26-year-old male and a 20-year-old. Any info? DM @NYPDTips, or anonymously call them at 800-577-TIPS.”

The suspect who shot at a group of people in the Bronx on June 25, 2021.
The suspect who shot at a group of people in the Bronx on June 25, 2021.
NYPD
The suspect firing the gun in the Bronx.
The suspect firing the gun in the Bronx.
NYPD
The shooting left two people injured, according to the NYPD.
The shooting left two people injured, according to the NYPD.
NYPD

The 26-year-old was shot in the buttocks and the 20-year-old was shot in the leg, police said. Both were expected to survive.

The victims said they were standing with a group of friends when the “guy just came up and started shooting,” a police spokesman said.

No words were exchanged, video shows. 

There were no immediate arrests.

Source link



[ad_2]

Source link

Continue Reading

US

FDA finds peeling paint, debris at US plant making J&J’s COVID vaccine

Published

on

By

[ad_1]

A US plant that was making Johnson & Johnson’s COVID-19 vaccine must fix a long list of problems including peeling paint and unsanitary conditions and practices to resume operation, according to a highly critical report by the Food and Drug Administration.

Experts said addressing the issues raised in the scathing FDA inspection report could take months.

Neither J&J nor the FDA has said when they expect vaccine production to restart at the Baltimore plant owned by Emergent Biosolutions. Only two other plants are currently equipped to supply the world with the key drug substance for J&J’s vaccine.

“It may take many months to make these changes,” said Prashant Yadav, a global health care supply chain expert at the Center for Global Development. He described some of the issues raised by the FDA as “quite significant.”

No vaccine manufactured at the Emergent plant has been distributed for use in the United States. However, J&J said it will exercise its oversight authority to ensure that all of the FDA observations are addressed promptly and comprehensively.

The Johnson & Johnson vaccine was put on a pause in the US over a potential link to a blood clotting condition.
Getty Images

The health care conglomerate has drawn scrutiny for months over its halting process to scale up production of a vaccine that is easier to handle and, by virtue of being a single shot, easier to use than other authorized vaccines.

Its use in the United States has been paused since last week as health officials study a possible link to a very rare but serious blood clot condition.

Emergent has been seeking regulatory authorization to make the J&J vaccine in the United States. It stopped production at the plant recently, saying the FDA had asked it to do so after an inspection.

J&J’s plant in Leiden, the Netherlands, is still producing doses for the world. It has another facility in India, which is currently curtailing exports of the shot as it struggles to vaccinate its own population.

Johnson & Johnson reiterated on Wednesday that it was working to establish a global supply chain in which 10 manufacturing sites would be involved in the production of its COVID-19 vaccine, in addition to the Leiden plant.

The company has a US government-brokered agreement with rival drugmaker Merck, which is preparing to make doses of J&J’s vaccine.

Failure to train personnel

The FDA in its final 12-page inspection report said it had reviewed security camera footage in addition to an in-person site visit to the Emergent plant.

It found a failure to train personnel to avoid cross-contamination of COVID-19 vaccines from Johnson & Johnson and AstraZeneca, which had also been produced at the site. The agency also cited staff carrying unsealed bags of medical waste in the facility, bringing it in contact with containers of material used in manufacturing.

The FDA reviewed security camera footage and visited the Emergent BioSolutions plant in Baltimore.
Getty Images

Earlier this week, the House launched an investigation into whether Emergent used its relationship with a Trump administration official to get a vaccine manufacturing contract despite a record of not delivering on contracts.

Emergent said in a statement that it is working with the FDA and J&J to quickly resolve the issues outlined in the report.

Production of the AstraZeneca vaccine, which is not yet authorized for use in the United States, was previously stopped at the Emergent plant after ingredients from that shot contaminated a batch of J&J vaccine, ruining millions of doses.

The FDA also noted that Emergent did not produce adequate reports showing that the vaccines it was producing met quality standards.

The inspection, carried out between April 12 and April 20, also found the building not of suitable size or design to facilitate cleaning, maintenance or proper operations.

J&J said it was redoubling its efforts to get authorization for the facility as quickly as possible.

[ad_2]

Source link

Continue Reading

US

One dead after pair of fires breaks out in Manhattan

Published

on

By

[ad_1]

One person was killed and several others were injured in a pair of Manhattan fires Wednesday morning, officials said.

The first blaze erupted in Midtown around 8:15 a.m. inside a DSW Designer Shoe Warehouse at 213 W. 34th St., where an escalator became fully engulfed in flames — sending smoke billowing into the first and second floor and the interconnected 40-story hotel building, fire officials said.

It was not immediately clear which hotel it was.

Five firefighters suffered minor injuries putting out the blaze.

“The fire went out, but we have a smoke condition that we’re trying to alleviate,” FDNY Battalion Chief John Porretto said at the scene. “Units are going to remain on scene until all the smoke alleviates.”

The fire marshal will determine the causes of the fire.

A second blaze broke out 15 minutes later on the Upper East Side at 1576 2nd Ave., officials said.

A three-alarm fire at 213 W. 34th Street in Manhattan that left one dead
A three-alarm fire at 213 W. 34th St. in Manhattan left one dead.
NYFD

One man died in the fire and a second man was in serious condition at Lenox Hill Hospital, police said.

A firefighter suffered minor injuries battling the blaze and was taken to Cornell Hospital, fire officials said.

[ad_2]

Source link

Continue Reading

Trending